Journal article
PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival
C Rosty, JP Young, MD Walsh, M Clendenning, K Sanderson, RJ Walters, S Parry, MA Jenkins, AK Win, MC Southey, JL Hopper, GG Giles, EJ Williamson, DR English, DD Buchanan
Plos One | Published : 2013
Abstract
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3CA mutations relate to other molecular alterations in colorectal carcinoma, to pathologic phenotype and survival. PIK3CA mutation testing was carried out using direct sequencing on 757 incident tumors from the Melbourne Collaborative Cohort Study. The status of O-6-methylguanine-DNA methyltransferase (MGMT) was assessed using both immunohistochemistry and methyLight techniques. Microsatellite instability, CpG island phenotype (CIMP), KRAS and BRAF V600E mutation status, and pathology review features were derived from previous reports. PIK3CA mutation was observed in 105 of 757 (14%) of carcinom..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (509348 209057) and Cancer Council Victoria. MAJ is a NHMRC Senior Research Fellow and JLH is a NHMRC Australia Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.